Abstract:Insulin is a major regulator of cell metabolism but, in addition, is also a growth factor. Insulin effects in target cells are mediated by the insulin receptor (IR), a transmembrane protein with enzymatic (tyrosine kinase) activity. The insulin receptor, however, is represented by a heterogeneous family of proteins, including two different IR isoforms and also hybrid receptors resulting from the IR hemireceptor combination with a hemireceptor of the cognate IGF-1 receptor. These different receptors may bind insulin and its analogs with different affinity and produce different biologic effects. Since many years, it is known that many cancer cells require insulin for optimal in vitro growth. Recent data indicate that: (1) insulin stimulates growth mainly via its own receptor and not the IGF-1 receptor; (2) in many cancer cells, the IR is overexpressed and the A isoform, which has a predominant mitogenic effect, is more represented than the B isoform. These characteristics provide a selective growth advantage to malignant cells when exposed to insulin. For this reason, all conditions of hyperinsulinemia, both endogenous (prediabetes, metabolic syndrome, obesity, type 2 diabetes before pancreas exhaustion and polycystic ovary syndrome) and exogenous (type 1 diabetes) will increase the risk of cancer. Cancer-related mortality is also increased in patients exposed to hyperinsulinemia but other factors, related to the different diseases, may also contribute. The complexity of the diseases associated with hyperinsulinemia and their therapies does not allow a precise evaluation of the cancer-promoting effect of hyperinsulinemia, but its detrimental effect on cancer incidence and mortality is well documented.

The insulin-RB synapse in health and disease: cellular rocket science

The insulin superfamily of growth-promoting proteins

Tumor suppressor and anti-inflammatory protein: an expanded view on insulin-degrading enzyme (IDE)

Planet RB: a personal contribution to a proteomic map of human retinoblastoma protein

Antiproliferative MCR peptides block physical interaction of insulin with retinoblastoma protein (RB) in human lung cancer cells

Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies

Insulin, insulin receptors, and cancer

Recent Advances in Our Understanding of Insulin Action and Insulin Resistance

Deep mutational scanning of the human insulin receptor ectodomain to inform precision therapy for insulin resistance

How Insulin Binds to the Insulin Receptor: A Synthetic Chemical Biology Approach

Structural Resolution Of A Tandem Hormone-Binding Element In The Insulin Receptor And Its Implications For Design Of Peptide Agonists

Regulation of Insulin Receptor Trafficking by Bardet Biedl Syndrome Proteins

IRS proteins and beta-cell function.

Insulin-induced conformational changes in the full-length insulin receptor: structural insights gained from molecular modeling analyses

IRS proteins and the common path to diabetes

Modulation of insulin secretion by RBFOX2-mediated alternative splicing

Using site-directed mutagenesis to further the understanding of insulin receptor-insulin like growth factor-1 receptor heterodimer structure

Oncoprotein metastasis disjoined

A metabolic role for CD47 in pancreatic β cell insulin secretion and islet transplant outcomes

RB/E2F1 As a Master Regulator of Cancer Cell Metabolism in Advanced Disease.

Regulation of interlocking gene regulatory network subcircuits by a small molecule inhibitor of retinoblastoma protein (RB) phosphorylation: cancer cell expression of HLA-DR